All In Biotech

Drug Trial Radar · NCT02576717

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients

Last checked: Nov 20, 2026Latest source record: Jan 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,494

Actual

Start

Oct 16, 2015

Primary completion

Jan 5, 2023

Study completion Jan 5, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Oct 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the trial is to determine the safety and efficacy of RPC1063 in patients with relapsing multiple sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • RPC1063Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events (AEs)Time frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
  2. Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
  3. Number of Participants Experiencing Adverse Events (AEs) Leading to DiscontinuationTime frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
  4. Number of Participants Experiencing Adverse Events (AEs) Leading to WithdrawalTime frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
  5. Number of Participants Experiencing Adverse Events (AEs) of Special InterestTime frame: From first dose to 90-days post last dose (an average of 65 months up to a max of 85 months)
  6. Number of Participants With Abnormalities in Blood Absolute Lymphocyte Count (ALC)Time frame: From first dose up until last dose of study treatment (up to approximately 82 months)
  7. Number of Participants With Abnormalities in White Blood Cell Count (WBC)Time frame: From first dose up until last dose of study treatment (up to approximately 82 months)
  8. Number of Participants With Abnormalities in Blood Absolute Neutrophil Count (ANC)Time frame: From first dose up until last dose of study treatment (up to approximately 82 months)
  9. Number of Participants With Abnormalities in Specific Liver Function TestsTime frame: From first dose up until last dose of study treatment (up to approximately 82 months)
  10. Number of Participants With Electrocardiogram (ECG) Result AbnormalitiesTime frame: From first dose to 28-days post last dose (an average of 63 months up to a max of 83 months)
  11. Number of Participants With Clinically Relevant Abnormalities in Vital SignsTime frame: At baseline and 60 months after first dose of study therapy
  12. Number of Participants With Physical Examination AbnormalitiesTime frame: At baseline and every 12 months thereafter up until 84 months post first dose.
  13. Number of Participants Self-Identifying Suicidality by Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: At baseline and every 3 months thereafter up until 78 months post first dose.
  14. Number of Participants With Changes in Suicidality From Last Day on Treatment Per the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 1, 4, 7, 14, 21, 28, and 90 days post last dose.
  15. Change in Physician's Withdrawal Checklist (PWC-20) Total Score From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, and 90 days post last dose.
  16. Change in Hospital Anxiety and Depression Scale (HADS) Score From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, and 90 days post last dose.
  17. Changes in Epworth Sleepiness Scale (ESS) Score From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, and 90 days post last dose.
  18. Changes in Vital Sign Values From Last Day on TreatmentTime frame: 1, 4, 7, 14, 21, 28, and 90 days post last dose.

Locations

175 sites in 26 countries. Site status is shown where the registry gives one.

  • Local Institution - 115

    Phoenix, Arizona

  • Local Institution - 118

    Phoenix, Arizona

  • Local Institution - 110

    Berkeley, California

  • Local Institution - 103

    Fresno, California

  • Local Institution - 122

    Long Beach, California

  • Local Institution - 112

    Sacramento, California

  • Local Institution - 120

    San Francisco, California

  • Local Institution - 114

    Maitland, Florida

  • Local Institution - 123

    Port Charlotte, Florida

  • Local Institution - 124

    Sunrise, Florida

  • Local Institution - 147

    Tampa, Florida

  • Local Institution - 137

    Golden Valley, Minnesota

  • Local Institution - 170

    Las Vegas, Nevada

  • Local Institution - 143

    Raleigh, North Carolina

  • Local Institution - 107

    Westerville, Ohio

  • Local Institution - 144

    Knoxville, Tennessee

  • Local Institution - 138

    Lubbock, Texas

  • Local Institution - 179

    Round Rock, Texas

  • Local Institution - 141

    Kirkland, Washington

  • Local Institution - 907

    Grodno, Belarus

  • Local Institution - 904

    Homyel, Belarus

  • Local Institution - 902

    Minsk, Belarus

  • Local Institution - 901

    Minsk, Belarus

  • Local Institution - 903

    Minsk, Belarus

  • Local Institution - 905

    Vitebsk, Belarus

  • Local Institution - 906

    Vitebsk, Belarus

  • Local Institution - 256

    Bruges, Belgium

  • Local Institution - 255

    Brussels, Belgium

  • Local Institution - 252

    Montegnée, Belgium

  • Local Institution - 913

    Banja Luka, Bosnia and Herzegovina

  • Local Institution - 911

    Sarajevo, Bosnia and Herzegovina

  • Local Institution - 453

    Sofia, Bulgaria

  • Local Institution - 454

    Sofia, Bulgaria

  • Local Institution - 452

    Sofia, Bulgaria

  • Local Institution - 456

    Sofia, Bulgaria

  • Local Institution - 457

    Sofia, Bulgaria

  • Local Institution - 460

    Sofia, Bulgaria

  • Local Institution - 455

    Sofia, Bulgaria

  • Local Institution - 923

    Osijek, Croatia

  • Local Institution - 921

    Zagreb, Croatia

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.